Provost Miriam 4
4 · TransMedics Group, Inc. · Filed Dec 15, 2022
Insider Transaction Report
Form 4
Provost Miriam
VP of US Regulatory & FDA Rel.
Transactions
- Exercise/Conversion
Common Stock
2022-12-13$38.46/sh+5,918$227,606→ 19,469 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-12-13−5,918→ 15,105 totalExercise: $38.46Exp: 2031-02-24→ Common Stock (5,918 underlying) - Sale
Common Stock
2022-12-13$63.00/sh−1,620$102,060→ 15,154 total - Sale
Common Stock
2022-12-13$62.24/sh−2,695$167,737→ 16,774 total
Footnotes (4)
- [F1]The exercise followed the sell-to-cover process, whereby a portion of the shares acquired through the exercise were sold in the open market, with the proceeds used to fund the aggregate exercise price of the options.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $61.70 to $62.69, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $62.72 to $63.32, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on the fourth anniversary of the vesting commencement date, February 24, 2021.